A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation

BMC Psychiatry

Volumn 13, Issue , 2013, Pages

  Katagiri, Hideaki ^a   Fujikoshi, Shinji ^a   Suzuki, Takuya ^b   Fujita, Kiyoshi ^c   Sugiyama, Naoya ^d   Takahashi, Michihiro ^a,f   Gomez, Juan Carlos ^e  

^a Lilly Research Laboratories Japan   (Japan)

^b Department of Respiratory Medicine   (Japan)

^c Seishinkai Okehazama Hospital Fujita Kokoro Care Center   (Japan)

^d Numazu Chuo Hospital   (Japan)

^e ELI LILLY AND COMPANY   (United States)

^f Terauchi Takahashi Psychiatric Clinic   (Japan)

Author keywords

Acute psychotic agitation; Japanese; Rapid acting intramuscular olanzapine; Schizophrenia

Indexed keywords

OLANZAPINE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DSM-IV; ELECTROCARDIOGRAM; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SCHIZOPHRENIA; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT; AGED; CONTROLLED CLINICAL TRIAL; INTRAMUSCULAR DRUG ADMINISTRATION; JAPAN; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; JAPAN; MALE; MIDDLE AGED; PSYCHOMOTOR AGITATION; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

MLCS; MLOWN;

EID: 84872124728     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-13-20     Document Type: Article

References (27)

1. Krakowski M, Czobor P. Violence in psychiatric patients: the role of psychosis, frontal lobe impairment, and ward turmoil. Compr Psychiatry 1997, 38:230-236. 10.1016/S0010-440X(97)90031-6, 9202880.
2. Noble P, Rodger S. Violence by psychiatric in-patients. Br J Psychiatry 1989, 155:384-390.
3. Binder RL, McNiel DE. Emergency psychiatry: contemporary practices in managing acutely violent patients in 20 psychiatric emergency rooms. Psychiatr Serv 1999, 50:1553-1554.
4. American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia 2004, Arlington: American Psychiatric Publishing Inc, 2, American Psychiatric Association.
5. Thomas P, Alptekin K, Gheorghe M, Mauri M, Olivares JM, Riedel M. Management of patients presenting with acute psychotic episodes of schizophrenia. CNS Drugs 2009, 23:193-212. 10.2165/00023210-200923030-00002, 19320529.
6. Allen MH. Managing the agitated psychotic patient: a reappraisal of the evidence. J Clin Psychiatry 2000, 61(Suppl 14):11-20.
7. Addonizio G, Alexopoulos GS. Drug-induced dystonia in young and elderly patients. Am J Psychiatry 1988, 145:869-871.
8. Keck PE, Pope HG, Cohen BM, McElroy SL, Nierenberg AA. Risk factors for neuroleptic malignant syndrome. A case-control study. Arch Gen Psychiatry 1989, 46:914-918. 10.1001/archpsyc.1989.01810100056011, 2572206.
9. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000, 355:1048-1052. 10.1016/S0140-6736(00)02035-3, 10744090.
10. Buckley NA, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Saf 2000, 23:215-228. 10.2165/00002018-200023030-00004, 11005704.
11. Hatta K, Takahashi T, Nakamura H, Yamashiro H, Asukai N, Matsuzaki I, Yonezowa Y. The association between intravenous haloperidol and prolonged QT interval. J Clin Psychopharmacol 2001, 21:257-261. 10.1097/00004714-200106000-00002, 11386487.
12. Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry 2001, 62:153-157. 10.4088/JCP.v62n0303, 11305699.
13. Hatta K, Kawabata T, Yoshida K, Hamakawa H, Wakejima T, Furuta K, Nakamura M, Hirata T, Usui C, Nakamura H, Sawa Y. Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients. Gen Hosp Psychiatry 2008, 30:367-371. 10.1016/j.genhosppsych.2008.03.004, 18585542.
14. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ. WFSBP Task Force on Treatment: World Federation of Societies of Biological Psychiatry (WFSBP)_Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia. World J Biol Psychiatry 2005, 6:132-191. 10.1080/15622970510030090, 16173147.
15. Dahl SG. Pharmacokinetics of antipsychotic drugs in man. Acta Psychiatr Scand Suppl 1990, 358:37-40.
16. Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka KJ, Saunders JC, Krueger J, Bradley P, San L, Bernardo M, Reinstein M, Breier A. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001, 158:1149-1151. 10.1176/appi.ajp.158.7.1149, 11431240.
17. Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, Taylor CC, Palmer R, Dossenbach M, Kiesler G, Brook S, Wright P. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002, 59:441-448. 10.1001/archpsyc.59.5.441, 11982448.
18. Detke HC, McDonnell DP, Brunner E, Zhao F, Sorsaburu S, Stefaniak VJ, Corya SA. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry 2010, 10:43. 10.1186/1471-244X-10-43, 2895589, 20537128.
19. Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, McDonnell D. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010, 167:181-189. 10.1176/appi.ajp.2009.07081221, 20008947.
20. Allen MH, Currier GW, Carpenter D, Ross RW, Docherty JP. The expert consensus guideline series. Treatment of behavioral emergencies. 2005. J Psychiatr Pract 2005, 11(1):5-108. 10.1097/00131746-200501000-00002, 16319571.
21. Kay SR, Sevy S. Pyramidical model of schizophrenia. Schizophr Bull 1990, 16:537-545. 10.1093/schbul/16.3.537, 2287938.
22. Kay SR, Opler LA, Fiszbein A, Ramirez PM, Opler M, White L. Positive and Negative Syndrome Scale (PANSS) Technical Manual 2006, North Tonawanda: Multi-Health System Inc..
23. Ono H. Agitation-Calmness Evaluation Scale (ACES) for evaluation of psychomotor excitation and sedation. Japanese Journal of Clinical Psychopharmacology 2007, 10:1063-1066.
24. Inada T. Assessment and Diagnosis of Drug-induced Extrapyramidal Symptoms; Explanation and Usage Guide of DIEPSS 1996, Tokyo: Seiwa Shoten.
25. Katagiri H, Ono H, Fujikoshi S, Takahashi M. Placebo-controlled double-blinded study of olanzapine rapid-acting intramusclar injection in Japanese patients with schizophrenia presenting psychomotor excitation. Journal of New Remedies and Clinics 2012, 61:30-41.
26. Ono H, Fujikoshi S, Oka T, Sugiura S, Endo G, Takahashi M. A double-blind dose-response study comparing rapid acting intramuscular olanzapine and placebo in agitated schizophrenia. Journal of New Remedies and Clinics 2009, 58:163-180.
27. Zyprexa® Relprevv™ US package insert 2011, Indianapolis, IN: Eli Lilly & Company, Zyprexa® Relprevv™.